<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00459537</url>
  </required_header>
  <id_info>
    <org_study_id>CSFO327N2303</org_study_id>
    <nct_id>NCT00459537</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis</brief_title>
  <official_title>A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety and tolerability of topical 10% terbinafine
      hydrogen chloride applied daily versus 5% amorolfine nail lacquer applied twice a week in
      patients with mild to moderate toenail onychomycosis, for a total treatment duration of 48
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks</measure>
    <time_frame>Week 52</time_frame>
    <description>Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks.</measure>
    <time_frame>Week 52</time_frame>
    <description>Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Patients for 48 Weeks.</measure>
    <time_frame>Week 52</time_frame>
    <description>Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and &lt;= 10% residual involvement of the target toenail.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mycological Cure at End of Study After Treating Patients for 48 Weeks</measure>
    <time_frame>Week 52</time_frame>
    <description>Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability Assessed by the Number of Participants With Adverse Events</measure>
    <time_frame>Week 52</time_frame>
    <description>Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE or SAE and death. Additional details can be found in the Adverse Event Section.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1029</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>Terbinafine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amorolfine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terbinafine hydrogen chloride</intervention_name>
    <description>10 % terbinafine hydrogen chloride (HCL)</description>
    <arm_group_label>Terbinafine</arm_group_label>
    <other_name>Lamisil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amorolfine nail lacquer</intervention_name>
    <description>5 % amorolfine nail lacquer</description>
    <arm_group_label>Amorolfine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and females 12 - 75 years of age

          -  Fungal toenail infection of one or both of the large (great) toenails

          -  The nail infection must be due to a dermatophyte, (mixed infections [dermatophyte and
             non-dermatophyte] are not allowed)

          -  The target toenail area must have at least 25% to no more than 75% disease involvement
             without spikes.

        Exclusion Criteria:

          -  Target foot must not have severe plantar (moccasin) tinea pedis that would require
             systemic therapy. Mild to moderate tinea pedis (athlete's foot) infection should be
             treated with terbinafine prior to baseline or at any time during the trial. Other
             topical treatments for athlete's foot may be recommended at the discretion of the
             investigator.

          -  Subjects must not have abnormalities of the nail that could prevent a normal appearing
             nail if clearing of infection is achieved

          -  No administration of systemic antifungal medications within 6 months prior to
             screening visit

          -  No application of prescription topical antifungal medications for toenail fungus
             within 3 months or other commercially available topical medications for toenail fungus
             applied directly to the toenails within 1 month prior to screening visit

          -  Patients with the target toenail involving the matrix (lunula) or having less than 2mm
             clear (unaffected) nail plate length beyond the proximal fold.

          -  Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic
             keratin between the nail plate and nail bed) on the target nail.

          -  No professional pedicures or application of any nail polish product or nail cosmetic
             to the toenails after the screening visit

          -  Known pregnancy or lactation at time of enrollment

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various Cities</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various Cities</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various Cities</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various Cities</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various Cities</city>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various Cities</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various Cities</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various Cities</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various Cities</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Various Cities</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Iceland</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2007</study_first_submitted>
  <study_first_submitted_qc>April 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2007</study_first_posted>
  <results_first_submitted>January 19, 2011</results_first_submitted>
  <results_first_submitted_qc>March 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 20, 2011</results_first_posted>
  <last_update_submitted>May 3, 2011</last_update_submitted>
  <last_update_submitted_qc>May 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Toenail fungus</keyword>
  <keyword>Onychomycosis</keyword>
  <keyword>Nail fungus</keyword>
  <keyword>Toenail fungal infection</keyword>
  <keyword>Tinea unguium</keyword>
  <keyword>Dermatophytes</keyword>
  <keyword>Foot dermatoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terbinafine</mesh_term>
    <mesh_term>Amorolfine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Terbinafine</title>
          <description>10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.</description>
        </group>
        <group group_id="P2">
          <title>Amorolfine</title>
          <description>5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="507"/>
                <participants group_id="P2" count="522"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="493">Participants who had at least one dose of study drug and one post-baseline safety assessment.</participants>
                <participants group_id="P2" count="512"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="441"/>
                <participants group_id="P2" count="446"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Terbinafine</title>
          <description>10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.</description>
        </group>
        <group group_id="B2">
          <title>Amorolfine</title>
          <description>5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="507"/>
            <count group_id="B2" value="522"/>
            <count group_id="B3" value="1029"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="425"/>
                    <measurement group_id="B2" value="410"/>
                    <measurement group_id="B3" value="835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="349"/>
                    <measurement group_id="B2" value="372"/>
                    <measurement group_id="B3" value="721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks</title>
        <description>Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.</description>
        <time_frame>Week 52</time_frame>
        <population>The Intent-to-treat population (ITT) population consisted of all patients who were randomized and dispensed study drug. Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine</title>
            <description>10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.</description>
          </group>
          <group group_id="O2">
            <title>Amorolfine</title>
            <description>5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks</title>
          <description>Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.</description>
          <population>The Intent-to-treat population (ITT) population consisted of all patients who were randomized and dispensed study drug. Last Observation Carried Forward (LOCF)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18"/>
                    <measurement group_id="O2" value="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Patients for 48 Weeks.</title>
        <description>Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and &lt;= 10% residual involvement of the target toenail.</description>
        <time_frame>Week 52</time_frame>
        <population>Intent-to-treat population, Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine</title>
            <description>10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.</description>
          </group>
          <group group_id="O2">
            <title>Amorolfine</title>
            <description>5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Patients for 48 Weeks.</title>
          <description>Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and &lt;= 10% residual involvement of the target toenail.</description>
          <population>Intent-to-treat population, Last Observation Carried Forward (LOCF)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.54"/>
                    <measurement group_id="O2" value="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mycological Cure at End of Study After Treating Patients for 48 Weeks</title>
        <description>Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes</description>
        <time_frame>Week 52</time_frame>
        <population>Intent-to-treat population, Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine</title>
            <description>10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.</description>
          </group>
          <group group_id="O2">
            <title>Amorolfine</title>
            <description>5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mycological Cure at End of Study After Treating Patients for 48 Weeks</title>
          <description>Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes</description>
          <population>Intent-to-treat population, Last Observation Carried Forward (LOCF)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
                <count group_id="O2" value="522"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.17"/>
                    <measurement group_id="O2" value="15.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability Assessed by the Number of Participants With Adverse Events</title>
        <description>Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE or SAE and death. Additional details can be found in the Adverse Event Section.</description>
        <time_frame>Week 52</time_frame>
        <population>The Safety population consisted of all patients that received at least one dose of study drug and had at least one post-baseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine</title>
            <description>10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.</description>
          </group>
          <group group_id="O2">
            <title>Amorolfine</title>
            <description>5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability Assessed by the Number of Participants With Adverse Events</title>
          <description>Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE or SAE and death. Additional details can be found in the Adverse Event Section.</description>
          <population>The Safety population consisted of all patients that received at least one dose of study drug and had at least one post-baseline safety assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="493"/>
                <count group_id="O2" value="512"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285"/>
                    <measurement group_id="O2" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE suspected related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE suspected related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug discontinuation due to an AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks.</title>
        <description>Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.</description>
        <time_frame>Week 52</time_frame>
        <population>The Per-protocol population (PP) consisted of ITT patients who completed the study without protocol deviations that led to exclusion according to criteria defined before database lock The per-protocol population was used to provide confirmation of efficacy findings from the ITT population. Last Observation Carried Forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Terbinafine</title>
            <description>10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.</description>
          </group>
          <group group_id="O2">
            <title>Amorolfine</title>
            <description>5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Cure at the End of Study After Treating Participants for 48 Weeks.</title>
          <description>Complete cure is defined as negative potassium hydroxide (KOH) microscopy and negative culture for dermatophytes and no residual involvement of the target toenail.</description>
          <population>The Per-protocol population (PP) consisted of ITT patients who completed the study without protocol deviations that led to exclusion according to criteria defined before database lock The per-protocol population was used to provide confirmation of efficacy findings from the ITT population. Last Observation Carried Forward (LOCF).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15"/>
                    <measurement group_id="O2" value="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks</time_frame>
      <desc>Safety population consisting of all patients who received at least one dose of study drug and had at least one post-baseline safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Terbinafine</title>
          <description>10% terbinafine hydrogen chloride (72.6 mg/ml nail lacquer). Patients applied one layer of the study medication once daily for 48 weeks, preferably at bedtime, to all affected toenails and allowed to dry.</description>
        </group>
        <group group_id="E2">
          <title>Amorolfine</title>
          <description>5% amorolfine nail lacquer. Patients applied study medication twice weekly for 48 weeks to all affected toenails.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Intervertebral disc displacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cyst removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="512"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="493"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="512"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

